Biomimetic Polymer-Based Nanomaterials for Immune-Responsive Hepatocellular Carcinoma Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Immunology

Background:

• Hepatocellular carcinoma (HCC) presents significant challenges due to late diagnosis, tumor heterogeneity, and limited treatment efficacy.
• Current immunotherapies like immune checkpoint inhibitors show variable success, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review the therapeutic potential of biomimetic polymer-based nanomaterials for HCC.
• To explore their design principles, immunological characteristics, and immune-modulating mechanisms.

Main Methods:

• Review of preclinical studies on biomimetic polymer nanomaterials for HCC.
• Analysis of nanoplatform design, liver immunology, and immune modulation.
• Evaluation of challenges and future perspectives for clinical translation.

Main Results:

• Biomimetic nanoplatforms improve drug delivery, immune evasion, and tumor accumulation.
• These materials enhance antigen presentation, immune modulation, and T-cell infiltration.
• Combination therapies with nanoplatforms and checkpoint inhibitors show promise in suppressing tumor growth.

Conclusions:

• Biomimetic polymer nanomaterials demonstrate significant therapeutic potential for HCC by modulating the tumor immune microenvironment.
• Overcoming challenges in fabrication, standardization, and long-term biosafety is crucial for clinical translation.